contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-achieved-its-business-target-for-medical-research-contacts-in-this-financial-year-early

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.

Nightingale Health

One of the company’s business targets was to conclude contracts in medical research with a total contract value of at least 3.2 MEUR during the financial year July 1,  2023 – June 30,  2024, which was achieved a few months before the end of the financial year. 

Translation: Original comment published in Finnish on 4/25/2024 at 10:43 pm EEST
&nbsp;One of the company&rsquo;s business targets was to conclude contracts in medical research with a total contract value of at least 3.2 MEUR during the financial year July 1,&nbsp; 2023 &ndash; June 30,&nbsp; 2024, which was achieved a few months before the end of the financial year. Considering the news flow of recent months, achieving the <a href="https://www.inderes.se/releases/inside-information-nightingale-health-achieves-one-of-its-business-targets-for-this-financial-year-by-winning-contracts-in-medical-research-with-a-total-contract-value-of-at-least-eur-32-million">target</a> was not a big surprise. Our forecasts already included an expectation of more research revenue than the targeted amount for the current financial year, so the release does not cause immediate pressure on forecasts. However, contract deliveries are probably not expected to happen during the current financial year, so contracts also provide a base for next year's revenue.
<h2>Research clients generate a good small income stream, even though commercial breakthrough is sought elsewhere</h2>
From the perspective of the foundation of Nightingale&rsquo;s growth story, we consider it valuable that the company can maintain its position as a blood analysis provider for research operators. We believe the growth in research data strengthens the company&rsquo;s moat in the research segment, as we suspect that blood samples analyzed with the company&rsquo;s technology constitute significant comparable research data globally. 
However, in the short term, the significance of customer relationships in the research segment is currently limited for the company. In terms of Nightingale&rsquo;s commercial breakthrough, we consider the progress of the ramp-up of Terveystalo and pathology Asia customers, as well as possible news on signing agreements aimed at analyzing recurring large blood sample flows key. 
On the other hand, some research clients belong to the same <a href="https://www.inderes.se/analyst-comments/nightingale-opens-its-own-laboratory-in-the-us-and-wins-a-new-customer">group of companies</a> with clinical operators. Servicing such customers in research use in addition to strengthening basic revenue and the scientific base of the technology also gives Nightingale the option to expand the customer relationship into more commercially significant clinical use in the future.

Inderes

Nightingale achieved its business target for medical research contacts in this financial year early

	2023	24e	25e
Omsättning	4,2	4,7	8,7
tillväxt-%	80,80 %	12,78 %	85,00 %
EBIT (adj.)	−18,5	−17,8	−17,6
EBIT-%	−442,95 %	−377,50 %	−201,86 %
EPS (adj.)	−0,30	−0,27	−0,27
Utdelning	0,00	0,00	0,00
Direktavkastning
P/E (just.)	-	-	-
EV/EBITDA	0,77	-	-

Research clients generate a good small income stream, even though commercial breakthrough is sought elsewhere

Nightingale Health

Key Estimate Figures08/03

Beställ vårt nyhetsbrev — inget användarkonto krävs!